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Background: The aim of this study was to investigate the effect of combining rhFGF18 or BMP-7 with a biphasic
collagen/GAG osteochondral scaffold (Chondromimetic) on the repair of osteochondral defects in sheep.
Methods: Osteochondral defects (5.8x6mm) were created in the medial femoral condyle (MFC) and the lateral
trochlea sulcus (LTS) of the stifle joint of 24 female sheep. Sheep were randomly assigned to four groups (n = 6);
1) empty defect, 2) scaffold only, 3) scaffold + rhFGF-18 (30 μg) and 4) scaffold + BMP-7 (100 μg). At 6 months the
defects underwent non-destructive mechanical testing, gross assessment of repair tissue (ICRS score) and histological
analysis (Modified O’Driscoll score).
Results: ICRS repair score: Defects treated with scaffold + rhFGF18 (mean 9.83, 95% CI 8.43-11.23) and scaffold + BMP-7
(10, 9.06-10.94) in the MFC had significantly improved ICRS scores compared to empty defects (4.2, 0–8.80) (p = 0.002).
Mechanical properties: BMP-7 treated defects (mean 64.35, 95% CI 56.88-71.82) were significantly less stiff than both
the rhFGF18 (mean 84.1, 95% CI 76.8-91.4) and empty defects in the LTS, compared to both contralateral limb
(p = 0.003), and the perilesional articular cartilage (p < 0.001). Histology: A statistically significant improvement in the
modified O’Driscoll score was observed in the rhFGF18 treated group (mean 16.83, 95% CI 13.65-20.61) compared to
the empty defects (mean 9, 95% CI 4.88-13.12) (p = 0.039) in the MFC. Excellent tissue fill, lateral integration and
proteoglycan staining was observed. Only the rhFGF18 defects showed pericellular type VI collagen staining with
positive type II collagen and reduced positive type I collagen staining. The majority of defects in the control and BMP-7
groups demonstrated fibrocartilagenous repair tissue.
Conclusion: Statistically significant improvements in gross repair, mechanical properties and histological score were
found over empty defects when Chondromimetic was combined with rhFGF18. These results suggest that rhFGF18
may play a significant role in articular cartilage repair applications.
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There have been many technological advances in articular
cartilage repair techniques over the past decade but the
ability to regenerate hyaline cartilage continues to elude
us. Procedures such as autologous chondrocyte trans-
plantation and microfracture have, at best, been able to
produce a repair tissue with hyaline like features [1]. More
recently, a greater focus has been placed on the influence* Correspondence: alan.getgood@uwo.ca
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in any medium, provided the original work is pof subchondral bone in the disease process, with articular
cartilage now being properly recognised as a composite
structure [2]. As a result, tissue engineering principals are
now starting to be applied to regenerate the osteochondral
unit.
It has been demonstrated that osteochondral defects
show improved repair parameters when a scaffold is
used within the lesion [3]. Of the scaffolds used, a
novel biphasic osteochondral scaffold (Chondromimetic,
Orthomimetics/TiGenix, Cambridge, UK) has shown
promise in early studies [4]. This collagen/chondroitin
sulphate/calcium phosphate scaffold was demonstrated tos an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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cartilage at a 6 month end point in the caprine knee [4].
Whilst these results are encouraging, it is likely that a
combination of a scaffold and bioactive molecules, such as
chondrogenic growth factors, will enhance the healing
process [3].
A number of growth factors have been tested both
in-vitro and in-vivo for their chondrogenic properties,
including insulin like growth factor 1 (IGF-1) [5] and bone
morphogenetic protein 7 (BMP-7) [6,7]. More recently,
fibroblast growth factor 18 (FGF18) has also been
reported to promote chondrogenesis [8,9]. FGF-18 is a
member of the FGF family, in which there are 23
members that bind to 4 structurally related high affinity
FGF receptor (FGFR1-4) tyrosine kinases. The essential role
of FGF’s in signalling in bone and cartilage metabolism is
evident from genetic diseases, such as achondroplasia,
which are associated with mutations in the FGFR gene.
Studies have shown that FGF18 acts as a ligand for the
FGFR3 receptor, expressed on proliferating and prehyper-
trophic chondrocytes. Liu et al. [10] demonstrated that, in
FGF18 knockout mice, the growth plate phenotype was
similar to that of mice lacking FGFR3 – there was a delay
in ossification and a reduced expression of osteogenic
markers. They also showed that in FGF18/FGFR3 knockout
mice, expanded zones of proliferating and hypertrophic
chondrocytes were formed, with increased chondrocyte
proliferation and differentiation. These negative effects in
the growth plate are in contrast to the positive effect on
mature chondrocytes. Ellsworth et al. have shown a signifi-
cant direct effect of FGF18 on the growth and proteoglycan
synthesis of mature murine and human chondrocytes [11].
An in-vivo study by Power et al. [12] demonstrated that the
addition of recombinant human FGF18 (rhFGF18) to
microfracture defects in sheep resulted in improved fill
and quality of repair tissue with characteristics of hyaline
cartilage.
It is therefore possible that FGF18 may play a role in the
control of both chondrocyte and bone cell behaviour in
tissue repair and warrants an investigation for its use in
osteochondral regeneration.
This study was designed to investigate the effect of adding
either rhFGF18 (Merck Serono, Darmstadt, Germany) or
BMP-7 to a biphasic collagen-glycosaminoglycan (collagen-
GAG) scaffold in an ovine osteochondral defect model. The
null hypothesis was that neither the addition of rhFGF18 nor
BMP-7 would improve the quality of osteochondral repair
tissue when compared to a defect filled with scaffold alone.
Methods
This study received approval from both local research
ethics committee (University of Cambridge Biomedical
Support Services) and the Home Office (United Kingdom
Home Office).Animals: A total of 24 skeletally mature female Welsh
Mountain sheep between the ages of 3 and 5 years old
were included in the study. Each treatment group
contained six sheep (n = 6).
Experimental design: For all animals, full thickness
osteochondral defects 5.8 mm wide by 6 mm deep were
created in the proximal lateral trochlea sulcus (LTS) and in
the medial femoral condyle (MFC) of the right stifle joint
using custom made instrumentation. Four treatment
groups were used; A - no scaffold in defect (‘empty defect’),
B - scaffold alone (‘scaffold’), C - scaffold plus rhFGF18
(Merck Serono, Darmstadt, Germany, (‘scaffold + rhFGF18’)
and D - scaffold plus BMP-7 (R&D systems, Abingdon, UK)
(‘scaffold + BMP-7’).
Animal anaesthesia, preparation and surgical technique:
Prior to surgery animals were selected at random and
identification ear tags applied. All animals had food and
water removed 24 hours before surgery. General anaesthe-
sia was induced with an injection of thiopentone (3 mg/kg)
into the external jugular vein. Maintenance was achieved
via inhalational anaesthetic of a mixture of isofluorane,
nitrous oxide and oxygen. Perioperative analgesia was pro-
vided by pre-operative intramuscular Carprofen (1.5 mg/ml)
and antibiotic prophylaxis was given via intramuscular
procaine penicillin (10 mg/ml).
The basic surgical procedure was identical for all subjects
and performed under strict asepsis by a single surgeon.
Each stifle was physically examined for any abnormalities
whilst anaesthetised. No gross instability or pathology was
found, therefore no animal was excluded from participation
within the study.
The animal was placed in a dorsal recumbency position
and, following surgical preparation, the right stifle joint
opened via a lateral parapatellar approach. Following
patella subluxation, the LTS defect was made 10 mm
distal to the top of the lateral trochlear ridge aligned with
the middle of the lateral trochlear groove. The MFC defect
was made 10 mm distal to the condyle groove junction
and aligned with the medial crest of the trochlear groove.
A 5.8 mm wide × 6 mm deep cylindrical defect was
created and a 6mm×6mm collagen-GAG scaffold plus
appropriate test substance placed into the defect.
Test substances were reconstituted and added to the
scaffold prior to commencing the skin incision. This
allowed at least 10 minutes for the growth factor to adsorb
on to the scaffold, prior to insertion into the defect.
rhFGF-8 was reconstituted via the directions of the
supplier with 0.9% saline and added to the scaffolds in a
concentration of 150 μg/ml, providing 30 μg per scaffold.
Lyophilised BMP-7 was reconstituted with 4 millimolar
HCL and applied to the scaffold in a concentration of
500 μg/ml, providing 100 μg per scaffold. This concentration
was chosen due to previous studies and following personal
communication [6].




Grade I Mild softening of the articular cartilage
Grade II Fibrillation and fissuring of chondral surface
Grade III Cracks in articular cartilage, no subchondral
bone exposed
Grade IV Full thickness chondral defects down to bone
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ensure a satisfactory rim fixation of the plug, following
which the joint was closed in a standard fashion. Post-
operatively, animals were allowed to fully weight bear, but
kept in small pens for 48 hours to reduce ambulation. All
animals were housed indoors for the remaining study
period in large pens, which allowed a moderate degree of
ambulation. Regular checks were made for any animal dis-
playing signs of postoperative discomfort with additional
postoperative analgesia given if required. All further treat-
ments were recorded as appropriate.
Necropsy: Animals were humanely sacrificed at 26 weeks
postoperatively using a lethal dose of sodium pentobarbital.
Outcome measures:
1) Gross Morphology - The joints were opened and the
surface of the osteochondral defect sites blindly scored
by 2 observers using the International Cartilage Repair
Society score (Table 1). The presence of degenerative
change was noted as per the Outerbridge score
(Table 2).
2) Mechanical testing - Each implant site underwent
non-destructive mechanical testing to determine
changes to the cartilage surface surrounding the
implant or empty defect. Measurements were taken in
duplicate from the centre of the osteochondral defect,




Level with surrounding cartilage 4
75% repair of defect depth 3
50% repair of defect depth 2
25% repair of defect depth 1
0% repair of defect depth 0
Integration to
border zone
Complete integration with border zone 4
Demarcating border <1 mm 3
¾ of graft integrated, ¼ with notable border
>1 mm
2
½ of graft integrated with surrounding
cartilage, ½ with a notable border >1 mm
1





Intact smooth surface 4
Fibrillated surface 3
Small, scattered fissures or cracks 2
Several, small or few but large fissures 1
Total degeneration of grafted area 0
Total 12the created osteochondral defect at the 12, 3, 6, and 9
o’clock positions, using a handheld digital durometer
(Shore S1, M scale, Instron Ltd, UK). A number
between 0–100 (arbitrary unit) would be given (with
an inbuilt calibrated error of +/−5) at each site and a
mean calculated. These measurements were then
repeated in the contralateral limb in the same anatomic
sites. The stiffness of the reparative tissue was then
expressed as percentage stiffness relative to the control
cartilage in the contralateral limb. This therefore
allowed a surrogate measure of stiffness to be made, as
previously published [4].
3) Histology - Specimens were decalcified in formic
acid/sodium citrate over two weeks and then
processed for routine paraffin embedding. Sections of
7 μm thickness were made through the central
portion of the defect. Sections were stained with
Safranin O/Fast Green. One slide from the centre of
each defect was blindly scored by two investigators
using a modified O’Driscoll score (Table 3) [13].
4) Immunohistochemistry - Immunohistochemistry
was performed as described previously [14]. The fol-
lowing primary antibodies were used in this study;
monoclonal mouse anti human type I collagen (MP
Biomedicals, US, 1 in 200 dilution), monoclonal mouse
anti human type II collagen (MP Biomedicals, US, 1 in
100 dilution) and monoclonal mouse anti-rabbit type
VI collagen (Abcam, UK, 1 in 500 dilution). Horserad-
ish peroxidase-conjugated secondary anti-rabbit and
mouse immunoglobulin were used as appropriate, and
the colour reaction developed with 0.1% 3′, 3-
diaminobenzidine tetrachloride (DAB)/0.01% hydrogen
peroxide. Normal species-specific serum was used as a
control in all experiments. The degree of positive
staining for types I, II and VI collagens was evaluated
by semi quantitative scoring on a scale of 1 to 4 for
intensity i.e. inconspicuous (1), mild (2), moderate (3),
and strong (4) [15]. In addition the location of type VI
immunoreactivity was noted i.e. pericellular or
territorial.
Statistical analysis: Statistical significance between groups
for each end point was determined using a one-way analysis
Table 3 Modified O’Driscoll Histology Score [13]
Characteristic Grading Score





II Structural A. Surface irregularity: Smooth and intact 2
Characteristics: Fissures 1
Severe disruption, fibrillation 0
B. Structural integrity: Normal 2
Slight disruption, including cysts 1
Severe lack of integration 0
C. Thickness: 100% of normal adjacent cartilage 2
50-100% or thicker than normal 1
0-50% 0
D. Bonding to adjacent
cartilage:
Bonded at both ends of graft 2
Bonded at one end/partially both ends 1
Not bonded 0
III Freedom from cellular changes of degeneration: Normal cellularity, no clusters 2
Slight hypocellularity, <25% chondrocyte
clusters
1
Moderate hypocellularity, >25% clusters 0
IV Freedom from degenerate changes in adjacent
cartilage:
Normal cellularity, no clusters, normal
staining
3
Normal cellularity, mild clusters, moderate
staining
2
Mild or mod hypocellularity, slight staining 1
Severe hypocellularity, slight staining 0
V Reconstitution of subchondral bone: complete reconstitution 2
greater than 50% reconstitution 1
50% or less reconstitution 0
VI Bonding of repair cartilage to denovo subchondral
bone:
complete and uninterrupted 2
<100% but >50% recon 1
<50% complete 0
VII Safranin O staining: > 80% homogenous positive stain 2
40-80% homogenous positive stain 1
<40% homogenous positive stain 0
TOTAL SCORE Max
27
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Where data sets within groups were not found to be
normally distributed, a non-parametric Kruskal-Wallis test
was instead used, with a post hoc Dunns multiple compari-
sons test. A level of p < 0.05 was accepted as significant in
all analyses. GraphPad Prism 5 statistical software package(Graphpad Software Inc., La Jolla, CA) was used for graph
production and data analysis.
Results
Gross morphology (Figure 1): At post-mortem two animals
in the empty defect group were shown to have sustained
Figure 1 Macroscopic observation of degenerative change in the MFC and LTS at necropsy. The horizontal bars represent the mean value.
Non-parametric analysis shows a statistically significant difference between the degeneration in the BMP-7 group compared with the scaffold
only (p = 0.038).
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an undisplaced fracture of the lateral trochlea sulcus
which was deemed to affect healing, and the second a
subluxated patella which would have influenced its weight
bearing properties. Degenerative change was seen in many
animals in the LTS, particularly in the empty defect and
scaffold only groups. Non-parametric analysis showed a
statistically significant difference between the degener-
ation in the BMP-7 group compared with the scaffold only
(p = 0.038). Two animals in the BMP-7 group were noted
to have osteophyte formation on the MFC.
ICRS repair score (Table 4 and Figure 2): Both rhFGF18
(mean 9.83, 95% CI 8.43-11.23) and BMP-7 (10, 9.06-10.94)
had significantly improved ICRS repair scores in the MFC
compared to empty defects (4.2, 0–8.80) (p = 0.002). A
trend towards improved repair was seen with both growth
factors in comparison to the scaffold only but no statistically
significant difference existed between groups (p > 0.05). No
differences were noted in the LTS.
Mechanical indentation (Table 5): In the MFC, no
differences existed between the treatment groups in
the mean percentage stiffness of the contralateral limb
(p = 0.31). In the LTS, BMP-7 was significantly less stiff
than both rhFGF18 and the empty defect when compared
to the cartilage of contralateral limb (p = 0.003). However,
the empty defects in the MFC were noted to have higher
mean stiffness measurements than normal.Table 4 Mean ICRS Repair Score for each category
Empty defect Scaff
MFC LTS MFC
I. Degree of defect repair 2.00 2.60 2.83
II. Integration to border zone 1.20 2.50 2.17
III. Macroscopic appearance 1.00 3.17 1.33
MEAN TOTAL SCORE 4.20 2.67 6.33
p < 0.05 * #
* and # indicate significant differences between specific groups p = 0.002. All otherHistology (Table 6 and Figure 3): A significantly higher
modified O’Driscoll score was seen in the rhFGF18 group
(mean16.83, 95% CI 13.65-20.61) in the MFC when
compared to the empty defect (9, 4.88-13.12) (p = 0.039)
(Figure 3). A similar trend was observed in the LTS, with
both the rhFGF18 and scaffold only groups scoring higher
than the empty defect, however no statistical significance
was reached. The BMP-7 group showed the worst results
of all in the LTS with a wide variability (7.83, 3.46-12.21)
Tissue repair: Tissue was seen to have filled the entire
original defect in the majority of animals (Figure 4). Good
tissue fill was noted in both the cartilaginous and osseous
parts of the repair in the empty, scaffold only and
rhFGF18 treated groups. In the BMP-7 treated group,
poor defect fill was seen in four of the six LTS defects with
very poor Safranin O staining in the other two defects. In
the MFC, the proteoglycan deposition was improved as
seen by increased Safranin O staining; however the thick-
ness of the cartilage layer was mostly reduced in compari-
son to the native cartilage. In addition, two of the six
BMP-7 treated MFC defects contained large subchondral
cysts (Figure 4D). In the empty defect and scaffold only
groups, moderately positive Safranin O staining was seen
in MFC defects, with relatively poor staining in the LTS in
scaffold only groups. In the rhFGF18 group excellent
Safranin O staining was present throughout the chondral
portion of all defects indicating good proteoglycanold only rhFGF18 BMP-7
LTS MFC LTS MFC LTS
2.20 3.83 1.60 4.00 6.40
2.67 3.67 1.33 3.50 6.50
2.33 2.33 1.83 2.50 7.33
2.50 9.83 1.00 10.00 6.50
* #
group comparisons p > 0.05.
Figure 2 International Cartilage Repair Society gross repair score of MFC and LTS. Box and whisker plots represent the maximum and
minimum values, the interquartile range with the horizontal bar representing the median value. Statistically significant differences were noted
between the empty defects and rhFGF18 and BMP-7 in the MFC (p = 0.002) while no difference was found between groups in the LTS (p > 0.05).
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parent cartilage was seen in the scaffold only and rhFGF18
groups, however in the BMP-7 group there was poor
lateral integration (Figure 5). Histology: In empty defects
there was disorganised cartilage tissue within the defect,
consistent with a fibrocartilagenous repair (Figure 6A). In
the scaffold only and BMP-7 groups there was more
organisation of the repair cartilage, albeit in defects with
poor tissue fill as noted above. In the lateral margins of
the repair tissue a more hyaline cartilage structure was
noted, with chondrocytes in lacunae arranged in columns
in the deep zone, with more flattened chondrocytes in the
superficial zone. A similar histological picture was noted
in the rhFGF18 group although the organised hyaline like
cartilage (Figure 6B) was present over a larger region of
the repair tissue with only a central zone showing fibro-
cartilagenous characteristics. Immunohistochemistry: In
all empty defects there was strong type I collagen staining
throughout the repair tissue. In the scaffold only and
BMP-7 groups both type I and type II collagen staining
was detected. In the rhFGF18 group there was negative
type I collagen staining and strong type II collagen. No
empty or BMP-7 treated defects stained positive forTable 5 Mechanical testing data
Empty defect Scaffold only
MFC LTS MFC
Mean 126.4 85.4 97.2
Std. Deviation 66.78 13.79 13.8
Std. Error 29.86 6.167 5.633
Lower 95% CI 43.46 68.28 82.72
Upper 95% CI 209.3 102.5 111.7
p < 0.05 *
* and # indicate significant differences between specific groups p = 0.003. All otherpericellular type VI collagen, pericellular type VI collagen
was only noted in the lateral margins of the repair tissue
in the scaffold only group while there was strong pericellular
type VI collagen throughout the majority of the rhFGF-18
defects (Figure 7).
The histology and immunohistochemistry results indi-
cated that, in the empty group there was a fibrocartilage
repair, in the scaffold only and BMP-7 defect groups there
was a predominately fibrocartilage repair with some
evidence of hyaline cartilage at the lateral margins of
the defect. In the rhFGF-18 treated group there was a
predominately hyaline cartilage repair with fibrocartilage
in the centre of the repair.
Discussion
This study has shown that the addition of rhFGF18 to a
collagen-GAG osteochondral scaffold can produce objective
improvements in osteochondral repair tissue in sheep,
when compared to defects either left empty, treated with
scaffold alone or when the scaffold is combined with BMP-
7. The addition of rhFGF18 resulted in statistically signifi-
cant improvements in gross appearance and histological
score over empty defects in the MFC. The combination ofrhFGF18 BMP-7
LTS MFC LTS MFC LTS
79.35 99.42 84.1 90.5 64.35
8.072 7.348 6.958 9.479 7.118
3.296 3 2.841 3.87 2.906
70.88 91.71 76.8 80.55 56.88
87.82 107.1 91.4 100.4 71.82
# * #
group comparisons p > 0.05.
Table 6 Mean Modified O’Driscoll score for each category
Empty defect Scaffold only rhFGF18 BMP-7
MFC LTS MFC LTS MFC LTS MFC LTS
I % Hyaline Cartilage: 0.80 1.00 1.00 1.67 3.00 2.00 1.33 0.00
II Structural Characteristics:
A. Surface Irregularity: 0.20 0.75 1.17 1.83 1.83 1.33 0.67 0.83
B. Structural integrity: 0.40 0.50 0.67 1.00 1.17 0.50 0.83 0.50
C. Thickness: 0.80 0.75 0.83 0.83 1.33 0.67 1.00 0.33
D. Bonding to adjacent cartilage: 1.20 1.00 2.00 1.50 1.83 1.67 2.00 1.17
III Freedom from cellular changes of degeneration: 0.60 0.25 0.67 1.00 0.83 0.83 1.00 0.50
IV Freedom from degenerate changes in adjacent cartilage: 1.80 1.75 2.17 1.50 2.33 2.33 2.50 2.33
V Reconstitution of subchondral bone: 1.00 0.75 0.33 0.67 0.67 0.83 1.17 0.50
VI Bonding of repair cartilage to denovo subchondral bone: 1.60 1.00 1.33 1.67 1.83 1.67 2.00 1.33
VII Safranin O: 0.60 0.50 1.00 1.00 2.00 1.33 1.50 0.33
MEAN TOTAL SCORE 9.00 8.25 11.17 12.70 16.83 13.20 14.00 7.83
p < 0.05 * *
* indicates significant differences between specific groups p = 0.039. All other group comparisons p > 0.05.
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anical properties to native articular cartilage, in contrast to
the BMP-7, which was found to be statistically less stiff than
both the empty defect and rhFGF18 in the LTS. Histologi-
cally, excellent tissue fill of the defects, lateral integration,
integrity of neocartilage, and expression of hyaline cartilage
markers, such as proteoglycan, type II collagen and pericel-
lular type VI collagen was also observed to a greater degree
with rhFGF18. Furthermore, along with BMP-7, rhFGF18
may provide a protective role against perilesional degener-
ation following osteochondral defect production in the
patellofemoral joint and warrants further investigation.
These findings support those of previous studies investi-
gating the role of FGF18 in chondrogenesis. Ellsworth
et al. [11] have shown that local delivery of adenovirus ex-
pressing FGF18 into the pinnae of nude mice increasedFigure 3 The modified O’Driscoll score for both MFC and LTS (p > 0.05)
differences were observed between the rhFGF18 and empty defects in the M
Box and whisker plots represent the maximum and minimum values, the intethe formation of auricular cartilage with high levels of
collagen type II and proteoglycan being expressed. Further
evidence of its chondrogenic effect were demonstrated
by the same group when rhFGF18 was injected intraven-
ously into rats, stimulating expansion of a number of
cartilaginous sites including trachea, spine and articular
cartilage [18]. In an osteoarthritis small animal model,
three injections of rhFGF18 were administered biweekly
into rat joints 21 days following meniscus transection [9].
Hyaluronic acid was used both as a carrier vehicle for
rhFGF18, and as the control injection. At 6 weeks his-
tological sections representative of the treatment groups
showed areas of chondrogenesis with increased proteogly-
can deposition and integration of the repair tissue with
the native cartilage matrix. Although the repair tissue was
not hyaline cartilage, it did show cellular organisation andshowing comparison between groups. Statistically significant
FC (p = 0.039) with no differences observed in the LTS between groups.
rquartile range with the horizontal bar representing the median value.
Figure 4 Histological sections stained with Safranin O. A) Empty defect, B) Scaffold alone, C) Scaffold + rhFGF-18, D) Scaffold + BMP-7. In A, B and
C there is good tissue fill. Differences in subchondral bone formation can be observed. The empty defect A shows subchondral hypertrophy, whilst in
C and D there appears to be a cartilage cleft, with significant proteoglycan staining extending down into the subchondral bone. In D there is a large
subchondral cyst. The arrows denote the margins of the defect.
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out any evidence of angiogenesis. A repair tissue, originat-
ing from the joint margins was also noted, migrating over
the cartilage surface. These responses were not seen within
the normal rat knee joints (i.e. those which were not sub-
jected to meniscus transection), indicating that rhFGF18
may exert its anabolic effects only on damaged cartilage. AFigure 5 Representative sections showing different grades of integratio
Black arrows indicate the junction between repair tissue and parent cartilage.
and the parent cartilage. B) There is integration in this section but a hypocellu
surface. C) Improved integration but hypocellularity at junction. D) Excellent i
tissue (right hand side of arrow).more recent study by Lohmander et al. [19] studied the
effects of intra-articular rhFGF18 injected into osteoarth-
ritic joints in a double blind, placebo controlled randomised
controlled trial. A statistically significant reduction in
joint space narrowing was noted in the lateral tibiofe-
moral compartment, yet no changes were noted in the
medial compartment, nor were changes noted in then of repair tissue to parent cartilage. Sections stained with Safranin O.
A) Poor repair tissue in the defect and no integration between this tissue
larity at the junction with a small area of fissuring on the articular
ntegration between repair tissue (left hand side of arrow) and parent
Figure 6 Histological sections stained with Safranin O. A)
Fibrocartilagenous repair tissue typical of that seen in empty defects,
scaffold alone and BMP-7, B) Hyaline cartilage-like repair tissue typical
of that seen in scaffold + rhFGF-18 treated defects.
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the mechanism of action of rhFGF18 is in some way de-
termined by the mechanical environment, as medial OA
is most often associated with varus alignment and rela-
tive offloading of the lateral compartment of the knee.
The above findings may have particular value in articu-
lar cartilage repair, as in the clinical scenario a mixed
picture of acute injury on a background of degenerative
disease can often be seen. During articular cartilage re-
pair surgery, it is often the case that the perilesional car-
tilage is diseased, yet the de novo repair tissue is
expected to integrate with it forming functional tissue.
Furthermore, it is common practice to ‘offload‘ the re-
pair tissue with a realignment osteotomy to improve the
mechanical environment. The possibility of a using agrowth factor to promote healing and repair within both
the defect and perilesional tissue is therefore appealing.
Surprisingly, BMP-7 performed relatively poorly in this
experimental study. BMP-7 is considered to be one of the
major anabolic growth factors of articular cartilage [20].
Although the gross repair scores were statistically superior
to the empty defect, two animals showed osteophyte
formation, a factor, which has been noted in a number of
other studies incorporating BMPs [21,22]. The histology
in the BMP-7 group, particularly the LTS, was very poor.
The majority of defects had poor tissue fill which stained
poorly for proteoglycan with architecture mostly resem-
bling fibrous tissue. In the MFC, two of the animals were
observed to have large cysts present within the subchon-
dral bone, which would likely provide sub-optimal clinical
results. As a result of this tissue repair, the mechanical
results were significantly inferior to both the rhFGF18 and
empty defect groups.
Most of the literature on BMP-7 suggests that it has a
acts as an anabolic growth factor, particularly for chondro-
cyte homeostasis and repair [6]. However, in this model,
the main cell type driving the repair process may not be
the chondrocyte per se, but is perhaps a mesenchymal
stem cell population, resident within the subchondral
bone or invading blood vessels, which may not be as
responsive to BMP-7 treatment. Knippenberg et al. [23]
have shown a preference of BMP-7 to direct chondrogenic
differentiation of adipose derived MSC’s, compared to an
osteogenic lineage by BMP-2. It therefore may not be as
potent a growth factor in osteochondral repair as
rhFGF18. Alternatively, the dose of BMP-7 used in this
model may not have been optimal. The dose of 100 μg per
scaffold was chosen based upon personal communication
with experts in the field who have previously studied OP-
1 (BMP-7) in in-vivo models of cartilage repair [6]. Ideally,
further studies should be performed to study different
concentrations of growth factor within this model to iden-
tify the optimal dose. It should also be noted that the
BMP-7 used in this study was not what has been used in
other studies provided by Stryker Biotech (Stryker,
Kalamazoo, MI), which may have an influence on its bio-
logical efficacy.
The positive effects of combining rhFGF18 with a
biphasic collagen-GAG scaffold to enhance osteochondral
repair is potentially very interesting. rhFGF18 is known to
exert an effect on chondrogenesis, as well as osteogenesis
[24], so clearly has potential to influence healing across
the osteochondral niche. One of the drawbacks of syn-
thetic polymer scaffolds has been reported to be delayed
bone formation [25], therefore the addition of a growth
factor into the construct, which may speed up the bone
regeneration process would be helpful. The ability to con-
trol the simultaneous repair of osteochondral tissue is yet
to be determined [26]. With increasing time there is a
Figure 7 Histological sections following immunohistochemistry to detect type VI collagen. A) Empty defect, B) Scaffold alone, C) Scaffold +
rhFGF-18, D) Scaffold + BMP-7. In A, where there is a fibrocartilagenous repair, there is little pericellular matrix staining with marked inter-territorial
matrix staining. In C there is marked pericellular staining (black rings around the cells) indicating a more hyaline cartilage like repair tissue.
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underway, which could result in an advancing tidemark,
chondrocyte hypertrophy and calcification of the articular
cartilage component of the osteochondral unit. The fact
that FGF18 seems to inhibit growth plate chondrocytes
may be somewhat protective of that process, however fur-
ther studies with longer time points until sacrifice would be
required to examine this further.
Limitations of this study include that the dosing schedule
may not have been optimal, with further injections of
rhFGF18 possibly providing greater benefit. The study time
also was only 6 months duration. A number of studies have
shown that articular cartilage repair can take upwards of
one year for maturation [27], therefore having animals out
to 12 months to see if these changes observed become
more pronounced or equilibrate, would be of interest. The
outcome measures used included a surrogate measure of
stiffness and semi quantitative histological analysis. Obtain-
ing objective measurements of stiffness and a biochemical
analysis of repair tissue would be advantageous, however
would have required a greater numbers of animals. As this
was a pilot study, the number of animals included was
deliberately reduced and therefore this extra analysis was not
possible. Furthermore, it is not clear if the findings, which
did not show statistical significance, could be secondary to
type II error. Further studies are therefore warranted with
larger numbers to ascertain the full potential of the drug.Conclusion
This study has demonstrated that the combination of
rhFGF18 and a collagen-GAG osteochondral scaffold canproduce objective improvements in osteochondral repair
when incorporated in an acute osteochondral defect model
in sheep, although topographic variation may exist between
the MFC and LTS. The use of rhFGF18 as a target molecule
for articular cartilage repair and osteoarthritis treatment
warrants further investigation.
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